



TERAPIA MULTIMODALE del Carcinoma Epatocellulare su Cirrosi

A. Giorgio

DIRETTORE IX DIVISIONE di MALATTIE INFETTIVE

ad INDIRIZZO ECOINTERVENTISTICO

AZIENDA OSPEDALIERA D.COTUGNO

NAPOLI

LIVER
TRANSPLANTATION

LIVER
RESECTION

PEI

MW

RF

ILP

HCC

TACE

Radiotherapy

HIFU

chemotherapy
hormone
therapy

Sopravvivenza del paziente con cirrosi e HCC non trattato

Anni	1	3	5
• Tang			
Cancer 1989	66%	10%	0%
• Ebara			
Gastroenterology 1986	90%	12%	-
• Livraghi			
J Hepatol 1995	86%	26%	11%
• Llovet			
Hepatology 1999	80%	65%	50%

LIVER
TRANSPLANTATION

LIVER
RESECTION

-FEASIBILITY

-SINGLE NODULE

-UP TO 3 NODULES

WITH MAXIMUM

DIAMETER = 3 CM

-YOUNG PATIENTS


-CHILD A CLASS

SCREENING E TERAPIA CHIRURGICA

- Screening : US , AFP, es.lab. ogni 6 mesi
- Follow-up medio 33 mesi :
38 (11,7%) nuovi HCC
(31 mononodulari)
 - Solo 22 (58%) resecabili o trapiantabili
 - A 12 mesi 13 casi di recidiva
 - A 12 mesi solo 9/38 (23%) erano liberi da malattia

HCC

- MULTIFOCALITY
- INTRAHEPATIC RECURRENCES
- PORTAL VESSELS INFILTRATION
- CIRRHOSIS
- COAGULATIVE DISORDERS



MINIMALLY INVASIVE
EFFECTIVE AND
REPEATABLE
THERAPY




Special article

Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference

Jordi Bruix*, Morris Sherman, Josep M. Llovet, Michel Beaugrand, Riccardo Lencioni, Andrew K. Burroughs, Erik Christensen, Luigi Pagliaro, Massimo Colombo, Juan Rodés, for the EASL Panel of Experts on HCC

Organizing Committee of the Conference: Henri Bismuth, Luigi Bolondi, Jordi Bruix and Daniel Shouval



Surgical resection, liver transplantation and percutaneous techniques achieve a relatively high rate of CR in properly selected candidates and thus should be classified as curative/effective treatments. At present, ethanol injection should be considered the standard percutaneous technique. Thus, more expensive and invasive options such as radio-frequency, micro-wave, cryotherapy or laser should be compared with PEI through RCTs assessing not only initial tumor response, but also long-term survival and costs.

Clinical management of hepatocellular carcinoma.
Conclusions of the Barcelona-2000 EASL Conference. J Hepatol 2001.

PRIMA



FASE PARENCHIMALE



FASE ARTERIOSA



FASE PARENCHIMALE



DOPO

PEI of HCC on CIRRHOSIS

CONVENTIONAL PEI
(SMALL TUMORS <3-5CM)

- Multiple sessions
- Out patients

ONE SHOT PEI
(LARGE AND MULTIPLE TUMORS)

- Single session
- Under general anesthesia

Percutaneous ethanol injection of HCC on cirrhosis

Ethanol induces:

- ❖ Coagulative necrosis for direct contact with malignant cells
- ❖ Ischemic necrosis for thrombosis of the small vessels of the tumor
- ❖ HCC is a soft tissue in a fibrotic liver
- ❖ Fine needle, low cost, repeatable

MATERIALS AND METHODS

CONVENTIONAL PEI


- ❖ Up to three nodules < 3 cm ;
 - ❖ Ethanol per session: 2-14 ml ;
 - ❖ Platelet count: > 50.000 ;
 - ❖ No sedation
- Fine needle: 22-21 G
Once - twice weekly on Out patients
PT: > 50%



Percutaneous Ethanol Injection Under Sonographic Guidance of Hepatocellular Carcinoma in Compensated and Decompensated Cirrhotic Patients

Antonio Giorgio, MD, Luciano Tarantino, MD, Giampiero Francica, MD, Vincenzo Scala, MD,


© 1992 by the American Institute of Ultrasound in Medicine • J Ultrasound Med 11:587-595, 1992



SURVIVAL RATES	1	2	3 YEARS
OVERALL	96%	86%	86%
CHILD A	100%	100%	100%
CHILD B	100%	100%	100%
CHILD C	81%	27%	0%
< 3 cm	100%	92%	92%
> 3 cm	90%	86%	-

Hepatocellular Carcinoma and Cirrhosis in 746 Patients: Long-term Results of Percutaneous Ethanol Injection

Tito Livraghi MD, Antonio Giorgio MD, Giuseppe Marin MD, Andrea Solmi MD, Ilario de Sio MD, Luigi Bolondi MD, Maurizio Pompili MD, Franco Brunello MD, Sergio Lazzaroni MD, Guido Torzilli MD, Alberto Zucchi MD.



Radiology 1995.

Complications

Death 1/1066 patients (0.09%)

Hemoperitoneum

Complications (no of cases): 34/1066 patients (3.2%)

Hemoperitoneum (5)

Hemobilia (2)

Subcapsular hematoma (1)

Parietal hematoma (1)

Intestinal perforation (1)

Acute cholangitis (1)

Early absces (2)

Thrombosis of the caval vein (1)

Thrombosis of the portal vein (3)

Pneumothorax (2)

Right pleural effusions (5)

Hepatic infarct (3)

Tumoral seeding (7)

Percutaneous Ethanol Injection under US guidance for Hepatocellular Carcinoma in Cirrhosis:

can indication be extended ?

The 4-year survival rate of patients with nodules > 3 cm was 79%. Multifocality did not affect survival.

**Giorgio A. , Tarantino L., de Stefano G. et al.
Radiology, November 1992; 185: 237.**



Percutaneous Ethanol Injection


One-Shot Percutaneous Ethanol Injection of Liver Tumors Under General Anesthesia: Preliminary Data on Efficacy and Complications

Antonio Giorgio,¹ Luciano Tarantino,¹ Giampiero Francica,¹ Nicola Mariniello,¹ Antonio Nuzzo,¹ Luca del Viscovo,² Antonio Rotondo²

¹Department of Infectious Diseases, Ospedale D. Cotugno, via Quagliariello, 1, Naples, Italy

²Department of Radiology, II Policlinico Università Federico II, Via Pansini, 5 Naples, Italy





One-Shot Percutaneous Ethanol Injection of Liver Tumors Under General Anesthesia: Preliminary Data on Efficacy and Complications

Antonio Giorgio,¹ Luciano Tarantino,¹ Giampiero Francica,¹ Nicola Mariniello,¹ Antonio Nuzzo,¹ Luca del Viscovo,² Antonio Rotondo²

¹Department of Infectious Diseases, Ospedale D. Cotugno, via Quagliariello, 1, Naples, Italy

²Department of Radiology, II Policlinico Università Federico II, Via Pansini, 5 Naples, Italy

- **EFFECTIVE IN INDUCING LARGE TUMOR NECROSIS**
- **SHORTENING THE TIME OF THE THERAPY**
- **HIGHER MORBIDITY COMPARED TO CONVENTIONAL PEI**
- **DEATH AS POSSIBLE COMPLICATION**
- **NOT MORE THAN 60 ml ETHANOL**

Clinical Science: Original Paper

Ultrasound-guided percutaneous ethanol injection under general anesthesia for the treatment of hepatocellular carcinoma on cirrhosis: long-term results in 268 patients

Antonio Giorgio ^{a,*}, Luciano Tarantino ^a, Giorgio de Stefano ^a,
Anna Perrotta ^a, Vincenza Aloisio ^a, Luca del Viscovo ^b, Alfredo Alaia ^c,
Gennaro Lettieri ^a



506/515 nodules

**Evaluated by
Enhanced CT**


COMPLETE NECROSIS

- **overall (357/506): 70%**
- **< 6 cm: 92%**
- **> 8 cm: 60%**

134/149 incompletely treated nodules were successfully retreated with conventional PEI or ONE-SHOT PEI

Survival curve

All cases



Survival rate of our series according to Child Pugh Class and the size of Tumor

Child Pugh'Class	1 year		2 year		3 year		4 year		5 year	
	SR	CI	SR	CI	SR	CI	SR	CI	SR	CI
A	98	(100-94)	88	(99-77)	79	(96-62)	70	(94-46)	70	(96-44)
B	94	(98-90)	85	(92-78)	76	(87-65)	67	(87-47)	54	(87-21)
C	60	(95-25)	24	(84-0)	-	-	-	-	-	-
Single nodule <5 cm	90	(97-83)	84	(95-75)	82	(98-66)	82	(100-51)	-	-
Single nodule >5 cm	97	(100-91)	71	(92-90)	59	(92-26)	59	(99-19)	59	(100-10)
Multiple nodules	97	(100-94)	89	(96-82)	75	(87-63)	60	(79-41)	60	(83-37)
Overall	93	(97-89)	83	(90-76)	74	(84-64)	65	(81-49)	59	(81-37)

*SR = Survival rate; CI, 95% = Confidence Interval (percentage)-

Giorgio A, Tarantino L, de Stefano G. et al. EJUS, 2000.

Complications

Five patients died

within 7hrs-10 days after the procedure

- ❖ Hemoperitoneum (1)
- ❖ Hemorrhage from rupture of aesophageal varices (3)
- ❖ Acute liver failure (1)

MAJOR COMPLICATIONS

- ❖ Hemoperitoneum (2; no need for blood transfusion)
- ❖ Acute tubular necrosis (2; only medical therapy)
- ❖ Decompensation of liver cirrhosis (8)

SELECTION CRITERIA

- ❖ **REFUSAL OF SURGERY**
- ❖ **SINGLE NODULE > 3 cm**
- ❖ **MULTIPLE NODULES**
(at least one > 3 cm; up to 6 nodules)
- ❖ **INTOLERANCE TO CONVENTIONAL PEI**
- ❖ **INCOMPLETE NECROSIS OF PREVIOUS CONVENTIONAL PEI**
(especially superficial nodules)

SELECTION CRITERIA

❖ ASCITES

❖ PARTIAL NEOPLASTIC THROMBOSIS
OF PORTAL VESSELS (Intrahepatic or
one of portal branches)

NOT ABSOLUTE CONTRAINDICATION

“Single Session “ Percutaneous Ethanol Injection: Conditions Considered at Risk

- ❖ **Marked portal hypertension**
- ❖ **Marked pulmonary hypertension**
- ❖ **Major heart disease**
- ❖ **Esophageal varices at risk of bleeding**
- ❖ **Hyperfibrinolysis**
- ❖ **Chronic DIC***
- ❖ **Chronic renal insufficiency**
- ❖ **Obstructive jaundice**
- ❖ **Superficial tumors with severe coagulation disorders**



**INTERSTITIAL
THERMAL
ABLATION**



Radiofrequency

Laser

Microwaves

Focused
Ultrasound

Una fibra ottica del calibro di 300 micron passa agevolmente attraverso un ago di Chiba sottile (21-22 G= 0.8 - 0.7mm)



**300 - 600 microm.
Fibra
ottica**

**↑
ago**

Clinical Science: Original Paper

Interstitial laser photocoagulation under ultrasound guidance of liver tumors: results in 104 treated patients

Antonio Giorgio ^{a,*}, Luciano Tarantino ^a, Giorgio de Stefano ^a,
Nunzia Farella ^a, Orlando Catalano ^b, Bianca Cusati ^b, Luca Del Viscovo ^c,
Alfredo Alaia ^d, Eugenio Caturelli ^e

^a *Interventional Ultrasound Service-D, Cotugno Hospital Naples, Viale colli Aminei 491, 80131 Naples, Italy*

^b *Department of Radiology, S. Maria delle Grazie Hospital, Pozzuoli, Italy*

^c *Department of Radiology, II University of Naples, Naples, Italy*


^d *Department of Anesthesiology, D. Cotugno Hospital, Naples, Italy*

^e *Department of Gastroenterology, Casa Sollievo della Sofferenza, S. Giovanni Rotondo, Italy*

Received 5 January 2000; received in revised form 10 March 2000; accepted 20 March 2000

Interstitial
Laser
Photo
coagulation

**77 patients with 85 HCC nodules
diam. range:10 to 66 mm (mean 32)**



Post-treatment CT

-Complete necrosis: 70/85 HCC (82%) in 65 pts

-Incomplete necrosis: 12 HCC nodules in 9 pts

Follow-up : 2 to 12 months (mean 4.5).

All patients are alive.


local recurrence : 1 patient


(successfully retreated by one-shot PEI)


COMPLICATIONS

Ascites, severe jaundice: 3 cases
(One of these patients died for liver failure 2 months after ILP)

-Paralytic ileum 7 days after ILP1 case
(spontaneously resolved)







HCC VI SEGMENTO. $\varnothing = 26$ mm



24 h after treatment

84 cirrhotic patients

67 Child-Pugh A class
14 Child-Pugh B class.

(55 males; age range : 48 – 74 years)

95 nodules of HCC (7 patients with 2 and 2 with 3 nodules)

Diam. nodules : 1.5 and 8.5 cm (mean : 3.7 cm)

42 HCC nodules \leq 3 cm

45 ranged 3.1 and 5 cm

8 diameter > 5 cm



n. of nodules	Size	n. of sessions	electrode insertions per session	complete necrosis	partial necrosis	recurrences during the follow-up**
42	\leq 3 cm	1	1	40 (95%)	2 (5%)	1
30	3.1-4.0 cm	1	1	25 (83%)	5 (17%)	3
15	4.1-5.0 cm	1	2-3 *	7 (47%)	8(53%)	3
8	5.1-8.5 cm	2	3	1 (12%)	7 (88%)	6
Total, 95	range 1.5-8.5 cm			Total, 73 (77%)	Total, 22 (23%)	Total, 13 (14%)

Antonio Giorgio MD, Luciano Tarantino MD, Giorgio de Stefano MD et al.

PERCUTANEOUS ULTRASOUND GUIDED SALINE ENHANCED HIGH-FREQUENCY-INDUCED-THERMOTHERAPY (HiTT) OF HEPATOCELLULAR CARCINOMA . AJR August 2003

COMPLICATIONS

- **No major complication occurred**

- **Fever** (1-3 days) after treatment **52/84 (62%)**

- **Pain** (12-24 hours) after treatment **66/84 (78%)**

Pain-killer necessary only in 30/84 (36%) patients .

- **No cutaneous or abdominal wall seeding have been observed clinically and/or by US during the follow-up.**

Le procedure di TERMOABLAZIONE PERCUTANEA (RF, ILP) :

- sono meglio tollerate rispetto alla PEI

- Danno volumi di necrosi limitati (< 4 cm)

rispetto alle estese necrosi ottenibili con la PEI

- Sono limitate dall'effetto "cooling" dei vasi peritumorali

- Meno efficaci per lesioni ipervasculari



000

NO. 82/82
SERV. ECOINTERVENTISTICA-OSP. COTUGNO NA

000



NO. 118/118
SERV. ECOINTERVENTISTICA-OSP. COTUGNO NA

000

000



VII

PV

IVC

PV

IVC



NO. 113/118

SERV. ECINTERVENTISTICA-OSP. COTUGNO NA

ID: '02/01/31 F5

F5

23/24
40Hz

12:30:09
3.5
PWR: 100%

R10 G75 C3 A1

: ABDOM



▲ ▲ ▲ ▲



▲ ▲

4 ▶





5 ▶

665/668

VOLUME = 130 CC



ONE-SHOT PEI 45 cc



Confronto con altre metodiche terapeutiche

PEI e RF

Nessuna differenza statisticamente significativa

Complicanze > per RF

Numero di sedute < per RF

Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Livraghi T, et al. Radiology 1999; 210 (3): 655-661.

BIAS importante:

Selezione numerosità della casistica

Lencioni R et al. Small HCC in cirrhosis : randomised comparison of RF versus PEI. Radiology, july 2003

- **102 patients**
- **1 – 2 years survival rates : n.s.**
- **1 – 2 years event free survival rates :**
RF better than PEI

Conclusions : RF is superior to PEI with respect to local recurrence free survival rates



Azienda Ospedaliera "D. COTUGNO"
Napoli



ADVERSE EVENTS DURING RADIOFREQUENCY TREATMENT OF 582 HEPATIC TUMOR

T de Baère et al.

AJR Sept 2003

ADVERSE EVENTS DURING RADIOFREQUENCY TREATMENT OF 582 HEPATIC TUMOR

- 5- years period
- 312 pts
- 350 RF sessions: 124 intraoperative / 226 percutaneous
- 115 HCCs
- 467 Mts

T de Baère et al.

AJR Sept 2003

**ADVERSE EVENTS DURING RADIOFREQUENCY
TREATMENT OF 582 HEPATIC TUMOR**

Majors complications: 14%

5 deaths:

3/123 intraoperative; 2/216 percutaneous

**portal vein thrombosis 2/5 Cirrhotic Livers
p<0.00001 vs non Cirrhotic Livers during Pringle
maneuver**

Liver abscess: 7pts

P<0.00001 bilioenteric anastomosys

**T de Baère et al.
AJR Sept 2003**

**ADVERSE EVENTS DURING RADIOFREQUENCY
TREATMENT OF 582 HEPATIC TUMOR**

Pleural effusion: 5

Pneumothorax: 3

Subcapsular hematoma: 1



Skin burn: 5

Hemoperitoneum: 1

**T de Baère et al.
AJR Sept 2003**

RF vs PEI: Indicazioni elettive per RF

- **Ipertensione portale**
- **Noduli avascolari alla TC e nuovi mdc ecografici**
- **Noduli a “mosaico”**






R14 G65 C5 | A1

ddone



R17 G65 C5 | A1



128
-MAY-1937
-OCT-2002
:30:16.04
-434.0

I 3


10

C 2.00
II 120
170
0.75


A

VC10C
H-SP-CR

D1 1	2.1
An 1	27
D1 2	2.5
An 2	116




PEI: Unexpensive



RF: Highly expensive

ILP: moderately expensive

Al centro di tutte le metodiche non c'è la “tecnica” ma il PAZIENTE e ogni singola tecnica deve adeguarsi al paziente



⇒ **Numero dei noduli**

⇒ **Sede del nodulo e tipo macroscopico**




⇒ **Bilirubina – TP – Ipertensione portale**

Più metodiche possono essere utilizzate nello stesso paziente ma sempre tenendo conto del singolo caso specifico!!!

Quale tecnica di ablazione ? (la nostra esperienza)

- paz. classe Child-Pugh A o B - nodulo/i < 2 cm : **ILP o RF**
- paz. classe Child-Pugh A o B con nodulo/i >2 cm<5 cm: **RF**
- paz. classe Child-Pugh A o B con nodulo/i >5 cm< 6 cm:
multiple sessioni di RF o PEI in sessione singola
- paz. classe Child-Pugh A o B con grosso HCC (> 6 cm) :
singola o mult. sessioni di PEI in anestesia generale
- paz. con disordini emocoagulativi severi (plt < 50.000/mmcc; I.N.R. > 1.7) :
ILP o PEI (con aghi del calibro di 21-22 G)
- paz. Child B-C con piccolo HCC (< 3 cm) : **ILP**
- paz. Child C con medio, grosso HCC (> 3 cm) : **nessun trattamento**
- Persistenza di aree vitali residue dopo ablazione di large HCC :
PEI (RF o ILP in casi particolari)
- Piccoli noduli di recidiva a distanza dalla prima ablazione : **ILP , PEI**
- Paz. Child A o B con mult. aree tumorali ipervascolari e/o infiltranti : **TACE**

Ipervascularità arteriosa dell'HCC



CHEMOEMBOLIZZAZIONE ARTERIOSA TRANSCATETERE

(TACE)

- Efficace sulle neoplasie con importante apporto arterioso
- Mai necrosi completa. La periferia del tumore è irrorata anche dai vasi portalì
- Se non superselettiva ha effetto lesivo sulla funzionalità epatica .
- sempre una parziale irrorazione portale del tumore
- In studi randomizzati dubbia efficacia sulla sopravvivenza dei pazienti trattati .
- Pesanti effetti collaterali in alcuni casi
- Effetto puramente palliativo
- Migliori risultati con TACE segmentaria

CHEMOEMBOLIZZAZIONE ARTERIOSA TRANSCATETERE (TACE)

Come terapia neoadiuvante :

..la TACE preoperativa deve essere evitata nel caso degli HCC resecabili in quanto non migliora la sopravvivenza né riduce il rischio di nuove lesioni e può peggiorare le condizioni generali del paziente ..

Adachi et al. Cancer, 1993 ; Wu C et al. Br J Surg, 1995


Può tuttavia rendere possibile, mediante citoriduzione, l'indicazione alla resezione di una neoplasia prima giudicata non operabile

Tang Z World J Surg, 1995

In combinazione con la PEI (o altre tecniche di ablazione) :

La combinazione TACE + PEI non offre vantaggi rispetto alla sola PEI

Shiina S AIR, 1993 ; Tanaka K Radiology, 1992



**TRATTAMENTO DI
LESIONI
IPERVASCOLARI
NON EVIDENZIABILI
CON L'ECOGRAFIA**

Lo vede solo l'Ecografia




Li vede solo la TC

SOPRAVVIVENZA

ANNI	3	5
OLT	72 %	65%
RESEZIONE	71%	51%
PEI	74%	47%
RF	76%	33%
MW	56%	56%
TACE segm.	72%	44%

Non esistono trials randomizzati e le casistiche non sono comparabili .



ELEGIBILE PER RESEZIONE

SI

CHIRURGIA

RECIDIVA

1-3 NODULI < 2 CM

ILP O PEI

NO

1-3 NODULI >2 < 5 cm

SI

RF

RECIDIVA

NO

LARGE HCC > 5 cm

SI

ONE-SHOT PEI ; RF + PEI

**NUMEROSI NODULI,
esteso HCC INFILTRANTE**

CHILD A o B

TACE ; TACE + PEI



Ultrasonics International 2003

30 June – 3 July 2003

Granada Conference and Exhibition Centre, Spain

1-3 July 2003

Conference – Ultrasonics International 2003

High intensity focused ultrasound surgery – should surgeons be worried about their futures?


Gail ter Haar

Physics department, Institute of Cancer Research: Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, UK



Principle of extra-corporeal high-intensity focused ultrasound surgery / Liver

Ultra
source



HIFU

- The technique has been demonstrated in over 2000 patients worldwide to be a safe and effective method of ablating tissue at depth without damage to intervening tissues.
- In many cases, this has been done as an outpatient technique without the need for anesthetic or sedation.
- It now seems likely that there are a number of applications for which HIFU will become the treatment of choice.

HIFU

- A total of 1038 patients underwent HIFU ablation in ten Chinese Hospitals.
- Pathological examination showed clear evidence of cellular destruction.
- Follow-up DSA, CT, MR and color Doppler US showed that there was no blood supply in the treated tumors.
- Among patients treated with HIFU an extremely low major complications rate was observed.
- It is concluded that HIFU ablation is a safe, effective and feasible modality for the ablation of liver carcinoma.